Acambis retained by Merrill Lynch at neutral

Acambis was retained by Merrill Lynch analysts Peter Welford and Erica Whittaker at a neutral rating as the market potential and strategy for the company's vaccines remain uncertain. A recent research-and-development day highlighted significant future opportunities for ChimeriVax-JE, ChimeriVax-West Nile and the CDAD toxoid vaccines, but the path to market and sales forecasts are challenging to project at this time. Shares of the Cambridge, England, vaccines company were down £0.5635, or 7.14%, at £7.3265 on volume of 31,173 shares versus the three-month running average of 21,439.4 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.